IBIO · iBio, Inc. · Documents
$0.77
+0.06 (+8.47%)
At close · Oct 27
Return incl. dividend (before tax)
Q4 2022 earnings call transcript
Going-concern doubt
— cleared Aug 28, 2026
The latest filing states the doubt was alleviated.
“The history of significant losses, the negative cash flow from operations, and the dependence by the Company on its ability to obtain additional financing to fund its operations in the past raised substantial doubt about the Company's ability to continue as a going concern. In August 2025, the Company closed an underwritten public offering raising gross proceeds of approximately $50 million and in January 2026, the Company raised gross proceeds of approximately $26 million in a private placement. Additionally, the Company received gross proceeds of approximately $33.4 million from the exercise of warrants during the year ended June 30, 2026. Based on the total cash and cash equivalents, and investments in debt securities of approximately $88 million at June 30, 2026, the Company believes that its current cash position is sufficient to fund its operations for at least 12 months from the date of filing this Annual Report on Form 10-K for the year ended June 30, 2026 (the “Annual Report”).”View the 10-K filed Aug 28, 2026
Market Cap
$49.32M
Shares
64.31M
Volume · Oct 27
478.17K
Avg daily vol (3M)
731.98K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | iBio stockholders increased authorized common shares from 275,000,000 to 500,000,000, effective October 16, 2026, and approved incentive-plan reserve increases of 5% plus 3% on January 1, 2027, January 1, 2028 and January 1, 2029. | 2026-10-19 | 2026-10-14 | |
| 8-K | iBio said IBIO-610 plus semaglutide resulted in lean mass making up 6% of weight loss in an eight-week NHP study, versus 22% with semaglutide alone; fat accounted for 93% versus 77%, and first-in-human studies are planned for first half of 2027. | 2026-10-13 | — | |
| 8-K | — | 2026-09-14 | — | |
| Investor Event Transcript | — | 2026-09-08 | 2026-03-31 | |
| ARS | — | 2026-09-04 | 2026-06-30 | |
| DEF 14A | — | 2026-09-04 | — | |
| 8-K | — | 2026-08-28 | — | |
| 10-K | — | 2026-08-28 | 2026-06-30 | |
| PRE 14A | — | 2026-08-20 | 2026-10-14 | |
| 8-K | — | 2026-08-04 | 2026-07-31 | |
| 8-K | — | 2026-07-17 | — | |
| 8-K | — | 2026-07-01 | — | |
| Investor Event Transcript | — | 2026-06-04 | 2025-12-31 | |
| 10-Q | — | 2026-05-12 | 2026-03-31 | |
| 8-K | — | 2026-05-12 | — | |
| 8-K | — | 2026-05-08 | 2026-05-07 | |
| 8-K/A | — | 2026-04-17 | 2026-04-08 | |
| 8-K | — | 2026-04-08 | — | |
| 8-K | — | 2026-03-09 | — | |
| 8-K | — | 2026-02-27 | 2026-02-23 | |
| S-3 | — | 2026-02-27 | — | |
| 8-K | — | 2026-02-10 | — | |
| 10-Q | — | 2026-02-10 | 2025-12-31 | |
| S-3 | — | 2026-01-30 | — | |
| 8-K | — | 2026-01-12 | 2026-01-08 | |
| 8-K | — | 2025-11-21 | 2025-11-20 | |
| 10-Q/A | — | 2025-11-17 | 2025-09-30 | |
| 8-K | — | 2025-11-17 | — | |
| 8-K | — | 2025-11-12 | — | |
| 10-Q | — | 2025-11-12 | 2025-09-30 | |
| 8-K | — | 2025-11-04 | — | |
| 8-K | — | 2025-10-30 | — | |
| DEF 14A | — | 2025-10-06 | 2025-11-20 | |
| ARS | — | 2025-10-06 | 2025-06-30 | |
| 10-K | — | 2025-09-05 | 2025-06-30 | |
| 8-K | — | 2025-09-05 | — | |
| 8-K | — | 2025-08-21 | 2025-08-19 | |
| 8-K | — | 2025-08-18 | — | |
| 8-K | — | 2025-08-01 | 2025-07-29 | |
| 8-K | — | 2025-06-24 | — | |
| 8-K | — | 2025-06-18 | 2025-06-17 | |
| S-3 | — | 2025-06-13 | — | |
| 10-Q | — | 2025-05-02 | 2025-03-31 | |
| 8-K | — | 2025-05-02 | — | |
| 8-K | — | 2025-04-22 | 2025-04-21 | |
| 8-K | — | 2025-04-08 | — | |
| 8-K | — | 2025-04-07 | — | |
| 8-K | — | 2025-02-19 | — | |
| 8-K | — | 2025-02-10 | — | |
| 10-Q | — | 2025-02-10 | 2024-12-31 |
Showing 1–50 of 240 filings